All Stories

  1. A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases

    Article • Therapeutic Innovation & Regulatory Science, May 2019, SAGE Publications

    Dr Charles Oo

  2. Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug development

    Article • Expert Review of Clinical Pharmacology, March 2016, Taylor & Francis

    Dr Charles Oo

  3. QT Correction: Using an Observed Regression Factor Applicable to a Population Subset

    Article • Journal of Pharmacy & Pharmaceutical Sciences, January 2016, University of Alberta Libraries

    Dr Charles Oo

  4. Orphan drug development for rare diseases: A golden opportunity or an unsustainable future?

    Article • The Journal of Clinical Pharmacology, September 2015, Wiley

    Dr Charles Oo

  5. There is no better time than the present: nanotechnology as a disruptive innovation for drug development

    Article • Drug Discovery Today, June 2015, Elsevier

    Dr Charles Oo

  6. Can CYP3A Activity Be Evaluated for Drug Interaction Using a Nanogram Dose of Probe Drug?

    Article • Clinical Pharmacology & Therapeutics, January 2014, Nature

    Dr Charles Oo

  7. In vitroandin vivometabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver

    Article • Xenobiotica, December 2013, Taylor & Francis

    Dr Charles Oo

  8. Does Erythromycin Have Anti-Inflammatory Effects Independent of Its Antimicrobial Action?

    Article • The Journal of Clinical Pharmacology, April 2012, Wiley

    Dr Charles Oo

  9. A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats

    Article • Journal of Pharmaceutical Sciences, January 2010, Elsevier

    Dr Charles Oo

  10. Population Pharmacokinetics of the Selective Serotonin 5-HT1A Receptor Partial Agonist Piclozotan

    Article • American Journal of Therapeutics, March 2009, Wolters Kluwer Health

    Dr Charles Oo

  11. The Need for Multiple Doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug-Drug Interaction Study

    Article • The Journal of Clinical Pharmacology, March 2009, Wiley

    Dr Charles Oo

  12. Reciprocating dialysis tube method: Periodic tapping improved in vitro release/dissolution testing of suppositories

    Article • European Journal of Pharmaceutics and Biopharmaceutics, November 2006, Elsevier

    Dr Charles Oo

  13. Oseltamivir Distributes to Influenza Virus Replication Sites in the Middle Ear and Sinuses

    Article • Clinical Drug Investigation, January 2004, Springer Science + Business Media

    Dr Charles Oo

  14. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1?5�years

    Article • European Journal of Clinical Pharmacology, September 2003, Springer Science + Business Media

    Dr Charles Oo

  15. Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules

    Article • International Journal of Pharmaceutics, May 2003, Elsevier

    Dr Charles Oo

  16. Safety and Pharmacology of Oseltamivir in Clinical Use

    Article • Drug Safety, January 2003, Springer Science + Business Media

    Dr Charles Oo

  17. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids

    Article • British Journal of Clinical Pharmacology, October 2002, Wiley

    Dr Charles Oo

  18. CHANGE IN CREATININE CLEARANCE WITH ADVANCING AGE

    Article • Journal of the American Geriatrics Society, September 2002, Wiley

    Dr Charles Oo

  19. Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin

    Article • Antimicrobial Agents and Chemotherapy, June 2002, ASM Journals

    Dr Charles Oo

  20. The Anti-Influenza Drug Oseltamivir Exhibits Low Potential to Induce Pharmacokinetic Drug Interactions via Renal Secretion—Correlation of in Vivo and in Vitro Studies

    Article • Drug Metabolism and Disposition, January 2002, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Charles Oo

  21. Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in Children

    Article • Pediatric Drugs, January 2001, Springer Science + Business Media

    Dr Charles Oo

  22. Active Transport of Nitrofurantoin into Rat Milk

    Article • January 2001, Springer Science + Business Media

    Dr Charles Oo

  23. Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults

    Article • Antimicrobial Agents and Chemotherapy, October 2000, ASM Journals

    Dr Charles Oo

  24. Clonazepam and Sertraline: Absence of Drug Interaction in a Multiple-Dose Study

    Article • Journal of Clinical Psychopharmacology, February 2000, Wolters Kluwer Health

    Dr Charles Oo

  25. Lack of effect of orlistat on the pharmacokinetics and pharmacodynamics of pravastatin

    Article • Clinical Pharmacology & Therapeutics, February 1999, Nature

    Dr Charles Oo

  26. Effect of Orlistat, a Novel Anti-Obesity Agent, on the Pharmacokinetics and Pharmacodynamics of Pravastatin in Patients with Mild Hypercholesterolaemia

    Article • Clinical Drug Investigation, January 1999, Springer Science + Business Media

    Dr Charles Oo

  27. Active transport of cimetidine into human milk*

    Article • Clinical Pharmacology & Therapeutics, November 1995, Nature

    Dr Charles Oo

  28. Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk.

    Article • British Journal of Clinical Pharmacology, September 1995, Wiley

    Dr Charles Oo